Belpointe Asset Management LLC purchased a new stake in Opko Health Inc. (NASDAQ:OPK) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 85,000 shares of the biotechnology company’s stock, valued at approximately $583,000.

Several other hedge funds and other institutional investors have also bought and sold shares of OPK. Cornerstone Capital Management Holdings LLC. increased its holdings in Opko Health by 611.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after acquiring an additional 1,242,272 shares during the period. Dimensional Fund Advisors LP increased its holdings in Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after acquiring an additional 2,241,103 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Opko Health by 43.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after acquiring an additional 471,256 shares during the period. Wells Fargo & Company MN increased its holdings in Opko Health by 14.3% during the 3rd quarter. Wells Fargo & Company MN now owns 481,085 shares of the biotechnology company’s stock worth $3,300,000 after acquiring an additional 60,177 shares during the period. Finally, Legal & General Group Plc increased its holdings in Opko Health by 17.4% during the 3rd quarter. Legal & General Group Plc now owns 141,535 shares of the biotechnology company’s stock worth $971,000 after acquiring an additional 21,017 shares during the period. 22.91% of the stock is currently owned by institutional investors.

A number of research firms recently weighed in on OPK. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a “buy” rating in a report on Thursday, October 12th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.97.

Opko Health Inc. (NASDAQ OPK) opened at $4.85 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health Inc. has a 12 month low of $4.50 and a 12 month high of $12.15.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The company had revenue of $263.50 million during the quarter, compared to analysts’ expectations of $319.43 million. During the same period in the prior year, the firm earned ($0.03) EPS. Opko Health’s quarterly revenue was down 11.6% on a year-over-year basis. equities research analysts forecast that Opko Health Inc. will post -0.27 EPS for the current fiscal year.

In other Opko Health news, major shareholder Opko Health, Inc. acquired 655,738 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was bought at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares of the company’s stock, valued at $20,370,193.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The stock was acquired at an average cost of $6.01 per share, with a total value of $90,150.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The disclosure for this purchase can be found here. In the last three months, insiders acquired 710,738 shares of company stock valued at $2,330,151. Corporate insiders own 40.19% of the company’s stock.

WARNING: “Belpointe Asset Management LLC Purchases Shares of 85,000 Opko Health Inc. (OPK)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/belpointe-asset-management-llc-purchases-shares-of-85000-opko-health-inc-opk/1765191.html.

Opko Health Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with Analyst Ratings Network's FREE daily email newsletter.